European Training Network on RNA Virus Replication and Antiviral Drug Develop...
European Training Network on RNA Virus Replication and Antiviral Drug Development
Virus infections remain a major cause of disease, with dramatic costs in mortality, morbidity, and economic loss worldwide. There is an unmet need for potent antiviral drugs, in particular against viruses with a (+)RNA genome whic...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
SILVER
Small molecule Inhibitor Leads Versus emerging and neglected...
22M€
Cerrado
ANTIVIRALS
European Training Network on Antiviral Drug Development
4M€
Cerrado
BICEPSvsHIV
Novel strategies for anti HIV 1 therapy Small molecules tar...
164K€
Cerrado
BES-2010-035087
IDENTIFICACION Y CARACTERIZACION DE RNAS NO CODIFICANTES QUE...
43K€
Cerrado
incPRINT-DRUG
incPRINT as a platform for RNA targeted drug discovery
150K€
Cerrado
MIMESIS
A novel systems biology approach to develop preclinical asse...
4M€
Cerrado
Información proyecto EUVIRNA
Líder del proyecto
UNIVERSITEIT UTRECHT
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
5M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Virus infections remain a major cause of disease, with dramatic costs in mortality, morbidity, and economic loss worldwide. There is an unmet need for potent antiviral drugs, in particular against viruses with a (+)RNA genome which include many important pathogens of humans and animals.
Antiviral drug development requires a detailed understanding of virus replication and effective translation of this knowledge into drug discovery. Europe needs well-trained experts with multidisciplinary skills to advance this field. However, few, if any, European training institutes have the broad know-how required to provide such a comprehensive training programme. The EUVIRNA partnership aims to fill this gap with the proposed EUVIRNA training programme.
The EUVIRNA partnership consists of six outstanding European academic partners and four industrial partners (one pharmaceutical R&D company and three SMEs), and an associated partner (SME specialized in education). All EUVIRNA partners are recognized leaders in their field, ensuring state-of-the-art training possibilities, and their skills are highly complementary. Three Visiting Researchers will complement the expertise of the partners.
EUVIRNA aims to introduce 18 ESR’s and 2 ER’s to state-of-the-art knowledge and technology applied in molecular virology and antiviral therapy, with both local and network-wide training activities. Individual research projects, research training workshops and intersectoral secondments will be supplemented with complementary skills courses to improve career development and perspectives. The industrial partners are actively involved in the entire programme, and will furthermore organize a 1-week industry-oriented conference aimed at further bridging the gap between academia and industry.
Thus, EUVIRNA offers talented researchers a multidisciplinary and intersectoral training programme and prepares them for a future leading role in European molecular virology research and antiviral dru